Viking Therapeutics Stock News

Viking and Nano-X are up-and-comers in healthcare with exciting products in the works. However, neither business is profitable, and it could be years before either one is.

After positive mid-stage data, Eli Lilly seems to have a chance at achieving best-in-class status in the valuable weight loss market. Viking's shares are sinking in response to this development.

Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.

A top competitor announced plans to move forward with a late-stage weight loss candidate today. Viking's weight-loss candidate is several years behind from a development standpoint.

With patent expirations around the corner, some of the biggest pharmaceutical and biotech companies will soon face generic competition, creating a big opportunity for these top biotech stocks to buy.

Investing in healthcare stocks can be a wise decision for those looking to become wealthy in the long term. Some of the best healthcare stocks to buy are firms that are developing highly effective dr

Alibaba has tremendous growth opportunities in AI. Intellia Therapeutics' gene-editing therapies hold the potential to be big winners.

Nano-X is marketing a different type of X-ray system. DermTech's Smart Sticker system could change dermatology.

Viking Therapeutics has a few drugs that have the potential to generate billions in revenue. The problem is that they are in early-stage trials, so there's ample uncertainty with the business.

Amylyx Pharmaceuticals and Viking Therapeutics have been on fire over the past year. Even so, both companies still look incredibly undervalued relative to their long-term growth potential.

Novo Nordisk's medicines for obesity and diabetes are spawning many copycats. Viking Therapeutics' stock is soaring thanks to its favorable early results.

Viking Therapeutics is a biotech with multiple potential blockbuster drugs in its portfolio. Encouraging trial results have made investors bullish about the stock's prospects.

Roth Capital Partners initiated coverage on Viking Therapeutics with a $32 per-share price target. The private investment banking firm also appears confident in the prospects of the company's lead ass

Two stocks in the healthcare sector have already doubled this year, and they could climb much higher, according to Wall Street. Viking Therapeutics is a clinical-stage biotech with an experimental tre

Now is a great time to start accumulating top biotech stocks. The biotech boom is red-hot.